JPWO2021132591A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021132591A5
JPWO2021132591A5 JP2021567687A JP2021567687A JPWO2021132591A5 JP WO2021132591 A5 JPWO2021132591 A5 JP WO2021132591A5 JP 2021567687 A JP2021567687 A JP 2021567687A JP 2021567687 A JP2021567687 A JP 2021567687A JP WO2021132591 A5 JPWO2021132591 A5 JP WO2021132591A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021567687A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021132591A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2020/048803 external-priority patent/WO2021132591A1/ja
Publication of JPWO2021132591A1 publication Critical patent/JPWO2021132591A1/ja
Priority to JP2022097020A priority Critical patent/JP7201192B2/ja
Publication of JPWO2021132591A5 publication Critical patent/JPWO2021132591A5/ja
Withdrawn legal-status Critical Current

Links

JP2021567687A 2019-12-26 2020-12-25 Withdrawn JPWO2021132591A1 (https=)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022097020A JP7201192B2 (ja) 2019-12-26 2022-06-16 エクソン50のスキッピングを誘導するアンチセンス核酸

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019236704 2019-12-26
PCT/JP2020/048803 WO2021132591A1 (ja) 2019-12-26 2020-12-25 エクソン50のスキッピングを誘導するアンチセンス核酸

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022097020A Division JP7201192B2 (ja) 2019-12-26 2022-06-16 エクソン50のスキッピングを誘導するアンチセンス核酸

Publications (2)

Publication Number Publication Date
JPWO2021132591A1 JPWO2021132591A1 (https=) 2021-07-01
JPWO2021132591A5 true JPWO2021132591A5 (https=) 2024-01-09

Family

ID=76574765

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021567687A Withdrawn JPWO2021132591A1 (https=) 2019-12-26 2020-12-25
JP2022097020A Active JP7201192B2 (ja) 2019-12-26 2022-06-16 エクソン50のスキッピングを誘導するアンチセンス核酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022097020A Active JP7201192B2 (ja) 2019-12-26 2022-06-16 エクソン50のスキッピングを誘導するアンチセンス核酸

Country Status (16)

Country Link
US (2) US20230073008A1 (https=)
EP (1) EP4083208A4 (https=)
JP (2) JPWO2021132591A1 (https=)
KR (1) KR20220122673A (https=)
CN (3) CN114901823A (https=)
AU (1) AU2020411964A1 (https=)
BR (1) BR112022012622A2 (https=)
CA (1) CA3165961A1 (https=)
CO (1) CO2022008664A2 (https=)
IL (1) IL294271A (https=)
MX (1) MX2022007937A (https=)
MY (1) MY209476A (https=)
PH (1) PH12022551431A1 (https=)
TW (2) TWI874546B (https=)
WO (1) WO2021132591A1 (https=)
ZA (1) ZA202206667B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293997A (en) * 2019-12-19 2022-08-01 Nippon Shinyaku Co Ltd Antistrand nucleic acids that allow exon skipping
CN114901823A (zh) * 2019-12-26 2022-08-12 日本新药株式会社 诱导外显子50的跳读的反义核酸
EP4458833A4 (en) 2021-12-27 2025-12-31 Nippon Shinyaku Co Ltd PROCESS FOR THE PRODUCTION OF OLIGONUCLEIC ACID COMPOUNDS
WO2023168427A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
AU655164B2 (en) 1989-12-20 1994-12-08 Antivirals Inc. Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages
JP2924179B2 (ja) 1993-02-19 1999-07-26 日本新薬株式会社 グリセロール誘導体,デバイス及び医薬組成物
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
EP2392660A3 (en) 2002-11-25 2012-03-28 Masafumi Matsuo ENA Nucleic Acid Drugs Modifying Splicing in mRNA Precursor
EP2933332A1 (en) 2004-06-28 2015-10-21 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
PL2735568T3 (pl) 2006-05-10 2018-02-28 Sarepta Therapeutics, Inc. Analogi oligonukleotydowe mające kationowe połączenia pomiędzy podjednostkami
WO2009005793A2 (en) 2007-06-29 2009-01-08 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
RU2606627C2 (ru) 2007-11-15 2017-01-10 Серепта Терапьютикс,Инк. Способ синтеза морфолиновых олигомеров
BR122020021379B1 (pt) * 2008-10-24 2021-05-11 Sarepta Therapeutics, Inc. oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular
AU2009310557B2 (en) 2008-10-27 2014-09-11 Academisch Ziekenhuis Leiden Methods and means for efficient skipping of exon 45 in Duchenne Muscular Dystrophy pre-mRNA
CN101388842B (zh) 2008-10-30 2012-04-04 华为技术有限公司 一种存储方法和装置
TR201816523T4 (tr) 2009-11-12 2018-11-21 Univ Western Australia Patolojilerin tedavisine yönelik antisens moleküller ve yöntemler.
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
CA3092114A1 (en) 2011-05-05 2012-11-08 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
CA2861247C (en) * 2011-12-28 2021-11-16 Nippon Shinyaku Co., Ltd. Antisense nucleic acids
US20140329762A1 (en) * 2013-03-15 2014-11-06 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
AU2016264471B2 (en) 2015-05-19 2022-01-27 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
AU2016302009B2 (en) 2015-08-05 2021-09-30 Eisai R&D Management Co., Ltd. Chiral reagents for preparation of homogeneous oligomers
IL295755A (en) 2015-10-09 2022-10-01 Wave Life Sciences Ltd Oligonucleotide compositions and methods thereof
EP3858993A1 (en) * 2015-10-09 2021-08-04 Sarepta Therapeutics, Inc. Compositions and methods for treating duchenne muscular dystrophy and related disorders
US20190330626A1 (en) * 2016-07-15 2019-10-31 Ionis Pharmaceuticals, Inc. Compounds and methods for use in dystrophin transcript
KR102810425B1 (ko) 2016-12-19 2025-05-21 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
KR20240006023A (ko) 2016-12-19 2024-01-12 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
PT3554552T (pt) 2016-12-19 2022-10-03 Sarepta Therapeutics Inc Conjugados de oligómero de skipping de exão para distrofia muscular
IL318474A (en) 2018-12-13 2025-03-01 Sarepta Therapeutics Inc Axon-skipping oligomer complexes for muscular dystrophy
CN114901823A (zh) * 2019-12-26 2022-08-12 日本新药株式会社 诱导外显子50的跳读的反义核酸

Similar Documents

Publication Publication Date Title
JP2023526975A5 (https=)
JP2025041734A5 (https=)
JP2021048879A5 (https=)
JP2023085489A5 (https=)
JP2021151238A5 (https=)
JP2023105131A5 (https=)
JP2025511899A5 (https=)
JP2021184963A5 (https=)
JP2022122972A5 (https=)
JP2024026077A5 (https=)
JP2022185040A5 (https=)
JP2023052878A5 (https=)
JP2022541332A5 (https=)
JP2023182571A5 (https=)
JP2023133317A5 (https=)
JP2021100406A5 (https=)
JP2020079331A5 (https=)
JP2022064180A5 (https=)
JP2022116141A5 (https=)
JP2022518056A5 (https=)
JP2023116477A5 (https=)
JP2022505925A5 (https=)
JP2022505923A5 (https=)
JP2023512729A5 (https=)
JPWO2021132591A5 (https=)